Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [517]
News [1431]
Articles [66]
Editorials [2]
Conferences [72]
elearning [5]
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients...
Dr Mario Sznol - Yale Cancer Center New Haven, USA
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma ( Dr Mario Sznol - Yale Cancer Center New Haven, USA )
1 Jun 2013
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2013
Prevention of squamous cell carcinoma
Dr Kenneth Tsai - MD Anderson Cancer Center, Houston, USA
Prevention of squamous cell carcinoma ( Dr Kenneth Tsai - MD Anderson Cancer Center, Houston, USA )
23 Apr 2013
Immunotherapy in melanoma and other cancers
Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA
Immunotherapy in melanoma and other cancers ( Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA )
19 Apr 2013
Intermittent treatment with vemurafenib may prevent lethal drug resistance in...
Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA...
Intermittent treatment with vemurafenib may prevent lethal drug resistance in melanoma ( Dr Darrin Stuart - Novartis Institutes for Biomedical Research, Emeryville, CA, USA )
8 Apr 2013
History of epidermal stem cell use in the clinical setting
Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy
History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )
14 Dec 2012
Analysing the efficacy of treatment through Response Evaluation Criteria in...
Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012
Phase III MISSION trial: Sorafenib does not extend overall survival as third or...
Dr Tony Mok – The Chinese University of Hong Kong
Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer ( Dr Tony Mok – The Chinese University of Hong Kong )
8 Oct 2012
Trametinib and dabrafenib combination therapy against metastatic melanoma
Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia
Trametinib and dabrafenib combination therapy against metastatic melanoma ( Dr Georgina Long – Westmead Hospital, The University of Sydney, Australia )
8 Oct 2012
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib...
Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia
BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma ( Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia )
29 Sep 2012
Phase I and II trials focus on drug combination slowing development of...
Prof Yossef Yarden - Weizmann Institute of Science, Israel.
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )
29 Sep 2012
The immuno side of melanoma
Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
The immuno side of melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
16 Jul 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation